Literature DB >> 8843634

DNA-mediated immunization to hepatitis B surface antigen: longevity of primary response and effect of boost.

H L Davis1, M Mancini, M L Michel, R G Whalen.   

Abstract

Intramuscular (i.m.) injection of mice with plasmid DNA expression vectors containing all or part of the hepatitis B virus (HBV) gene encoding the envelope proteins induces a strong humoral response to the HBV surface antigen (HBsAg) which is sustained for up to 74 weeks without boost. After a single i.m. injection of 100 micrograms DNA, antibodies to HBsAg (anti-HBs) reach ELISA titers of 4 x 10(4) in C57BL/6 mice and 10(4) in BALB/c mice, or somewhat less in older mice. Although antibody levels induced by a single injection of DNA do not diminish significantly over time, they can be further increased 10-200-fold by boosting with a second injection of DNA or an injection of recombinant HBsAg protein. Prior injection of DNA does not affect the strength or timing of the boosting effect, suggesting that there is no immune response against the vector itself. Boosting with a second injection of DNA is possible even in BALB/c mice, which are known to have a strong cytotoxic T-lymphocyte response against an epitope on the major HBV envelope protein, indicating that possible destruction of newly transfected muscle fibers is not so quick and efficient as to abort the boosting effect. A single injection of DNA results in a stronger and longer lasting humoral response than does a single injection of recombinant protein.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8843634     DOI: 10.1016/0264-410x(95)00255-y

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  26 in total

1.  Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies.

Authors:  C A Lobo; R Dhar; N Kumar
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

2.  Expression of domain III of the envelope protein from GP-78: a Japanese encephalitis virus.

Authors:  Sahil Kulkarni; Sandeepan Mukherjee; Krishna Mohan Padmanabha Das; Kaushiki Prabhudesai; Nupur Deshpande; Sushant Karnik; Abhay S Chowdhary; Usha Padmanabhan
Journal:  Virusdisease       Date:  2017-05-25

3.  Contribution of C3d-P28 repeats to enhancement of immune responses against HBV-preS2/S induced by gene immunization.

Authors:  Li-Xin Wang; Wei Xu; Qing-Dong Guan; Yi-Wei Chu; Ying Wang; Si-Dong Xiong
Journal:  World J Gastroenterol       Date:  2004-07-15       Impact factor: 5.742

4.  Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus.

Authors:  Judith H Aberle; Stephan W Aberle; Regina M Kofler; Christian W Mandl
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

Review 5.  [Molecular therapy in gastroenterology and hepatology].

Authors:  J Wedemeyer; N P Malek; M P Manns; M J Bahr
Journal:  Internist (Berl)       Date:  2005-08       Impact factor: 0.743

Review 6.  Hepatocellular carcinoma: therapy and prevention.

Authors:  Hubert E Blum
Journal:  World J Gastroenterol       Date:  2005-12-21       Impact factor: 5.742

7.  DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state.

Authors:  M Mancini; M Hadchouel; H L Davis; R G Whalen; P Tiollais; M L Michel
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

8.  CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice.

Authors:  C L Brazolot Millan; R Weeratna; A M Krieg; C A Siegrist; H L Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

Review 9.  DNA-antiviral vaccines: new developments and approaches--a review.

Authors:  M Giese
Journal:  Virus Genes       Date:  1998       Impact factor: 2.332

10.  Maternally transferred antibodies from DNA-immunized avians protect offspring against hepadnavirus infection.

Authors:  C Rollier; C Charollois; C Jamard; C Trepo; L Cova
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.